Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium

Thursday, November 15, 2007 General News J E 4
SAN JOSE, Calif., Nov. 14 VNUS(R) MedicalTechnologies, Inc. (Nasdaq: VNUS), a worldwide leader in medical devices forthe minimally invasive treatment of venous reflux disease, announced thatinterim results from two multi-center studies using the VNUS ClosureFASTcatheter were presented today at the 34th Annual VEITH Symposium in New York.The VNUS ClosureFAST(TM) catheter is an endovenous radiofrequency (RF)ablation catheter designed to heat and close diseased saphenous veins - theunderlying cause of varicose veins.

In a presentation titled "ClosureFAST Is Better Than First GenerationRadiofrequency Ablation: A Quantum Leap Forward", Alan Dietzek, MD., Chief ofVascular Surgery and Linda and Stephen R Cohen Chair in Vascular Surgery atDanbury Hospital in Danbury, Connecticut, presented one-year follow-up resultsof ClosureFAST patients from a multi-center prospective study including 13centers in the US and Europe. Among 324 patients (395 limbs) in the study, 142limbs had one-year followup data, with a vein occlusion rate of 96.2% at oneyear using Kaplan-Meier analysis.

"VNUS ClosureFAST is a major step forward in the management of venousdisease," said Dr. Dietzek. "Results so far have exceeded expectations,especially the excellent treatment efficacy combined with very mildpostoperative patient recovery. Furthermore, with ClosureFAST it is nowpossible to perform endovenous ablation of the saphenous vein as fast orfaster than with any other device or mode of treatment available."

Jose I. Almeida, MD., FACS, founder of the Miami Vein Center in Miami,Florida and a recognized expert in varicose vein treatment, presented theinterim results of the Recovery trial, a multi-center randomized trialcomparing the ClosureFAST treatment to endovenous laser. Patients undergoinglaser treatment were 33% more likely to experience pain and 50% more likely torequire postoperative pain medication than patients who received theClosureFast treatment.

"The ClosureFAST device is clearly emerging as the preferred treatment forvenous reflux, in part because of reduced patient discomfort after treatment,"said Dr. Almeida. "While procedure time and short-term efficacy are comparablebetween ClosureFAST and laser, we're definitely seeing a superior patientrecovery profile with ClosureFAST."

"We are pleased to see the positive interim study results on ourClosureFAST catheter, especially the favorable patient recovery profilecompared to laser treatment and the better-than-anticipated one-year efficacyrate," said Brian E. Farley, President and CEO of VNUS. "We believe the finalresults will support our belief that ClosureFAST is the best choice for thetreatment of venous reflux disease for the millions of varicose vein sufferersaround the world."


Now in its fourth decade, VEITHsymposium provides vascular surgeons,interventional radiologists, interventional cardiologists and other vascularspecialists with a unique and exciting format to learn the most currentinformation about what is new and important in the treatment of vasculardisease. The five-day event features rapid-fire presentations from worldrenowned vascular specialists with emphasis on the latest advances, changingconcepts in diagnosis and management, pressing controversies and newtechniques. VEITHsymposium is sponsored by The Cleveland Clinic, Cleveland,OH.


Founded in 1995 and headquartered in San Jose, California, VNUS MedicalTechnologies (Nasdaq: VNUS) is a worldwide leader in medical devices for theminimally invasive treatment of venous reflux disease, a progressive conditionthat causes the varicose veins afflicting 25 million Americans. The pioneeringcompany in the field, VNUS now offers the ClosureFAST system, which consistsof a proprietary radiofrequency (RF) generator and proprietary disposableendovenous


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Longs Drug Stores Corporation Reports 45% Increase...
AGD Announces Legislative Goals for Remainder of 1...